{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adverse+Events&page=28",
    "query": {
      "condition": "Adverse Events",
      "page": 28
    },
    "page_size": 10
  },
  "pagination": {
    "page": 28,
    "page_size": 10,
    "total_count": 1012,
    "total_pages": 102,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adverse+Events&page=29&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adverse+Events&page=27&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-02T15:32:03.837Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00436566",
      "title": "Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Cardiac Toxicity"
      ],
      "interventions": [
        {
          "name": "trastuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "doxorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "lapatinib ditosylate",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "gene expression analysis",
          "type": "GENETIC"
        },
        {
          "name": "reverse transcriptase-polymerase chain reaction",
          "type": "GENETIC"
        },
        {
          "name": "fluorophotometry",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "mass spectrometry",
          "type": "OTHER"
        },
        {
          "name": "adjuvant therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "quality-of-life assessment",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "GENETIC",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 122,
      "start_date": "2007-03-16",
      "completion_date": "2019-07-22",
      "has_results": true,
      "last_update_posted_date": "2022-08-05",
      "last_synced_at": "2026-11-02T15:32:03.837Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00436566"
    },
    {
      "nct_id": "NCT04818515",
      "title": "Study To Assess Adverse Events and Drug to Drug Interaction of Oral Tablet Atogepant and Ubrogepant in Adult Participants With a History of Migraine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Migraine"
      ],
      "interventions": [
        {
          "name": "Atogepant",
          "type": "DRUG"
        },
        {
          "name": "Ubrogepant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 26,
      "start_date": "2021-03-17",
      "completion_date": "2021-06-18",
      "has_results": false,
      "last_update_posted_date": "2022-06-16",
      "last_synced_at": "2026-11-02T15:32:03.837Z",
      "location_count": 3,
      "location_summary": "Orlando, Florida • Springfield, Missouri • West Bend, Wisconsin",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Springfield",
          "state": "Missouri"
        },
        {
          "city": "West Bend",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04818515"
    },
    {
      "nct_id": "NCT05283525",
      "title": "Efficacy Of Trimrox On Body Recomposition And Weight Management (TRCAP21)",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Body Weight Changes"
      ],
      "interventions": [
        {
          "name": "Anthropometric Measurement of the Chest, Upper Arm/Bicep, Hips, Thighs and Waist/ Belly in Inches",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Oxygen Saturation",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Total Blood Chemistry",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Adverse Event Monitoring",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Body Weight Monitoring",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Physical well-being including mood, energy, satiety level. sugar cravings, sleep, and overall health",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Victory Nutrition International, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "30 Years to 70 Years"
      },
      "enrollment_count": 100,
      "start_date": "2022-01-23",
      "completion_date": "2024-01-09",
      "has_results": false,
      "last_update_posted_date": "2022-03-17",
      "last_synced_at": "2026-11-02T15:32:03.837Z",
      "location_count": 1,
      "location_summary": "Huntingdon Valley, Pennsylvania",
      "locations": [
        {
          "city": "Huntingdon Valley",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05283525"
    },
    {
      "nct_id": "NCT00013143",
      "title": "Patient Profiling and Provider Feedback to Reduce Adverse Drug Events",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Adverse Drug Events"
      ],
      "interventions": [
        {
          "name": "Patient risk profiling (potential ADEs) w/provider feedback",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "US Department of Veterans Affairs",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1200,
      "start_date": "2001-06",
      "completion_date": "2003-01",
      "has_results": false,
      "last_update_posted_date": "2015-04-07",
      "last_synced_at": "2026-11-02T15:32:03.837Z",
      "location_count": 1,
      "location_summary": "West Los Angeles, California",
      "locations": [
        {
          "city": "West Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00013143"
    },
    {
      "nct_id": "NCT00002759",
      "title": "Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Drug/Agent Toxicity by Tissue/Organ",
        "Lymphoma",
        "Neutropenia",
        "Small Intestine Cancer",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "irinotecan hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "phenobarbital",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "1996-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-02-05",
      "last_synced_at": "2026-11-02T15:32:03.837Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002759"
    },
    {
      "nct_id": "NCT05269082",
      "title": "A Study to Assess the Hypersensitivity to TAK-880 Compared to Gammagard S/D in Blood of Children, Teenagers and Adults",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Drug Hypersensitivity"
      ],
      "interventions": [
        {
          "name": "No intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2022-04-05",
      "completion_date": "2022-09-19",
      "has_results": false,
      "last_update_posted_date": "2022-09-23",
      "last_synced_at": "2026-11-02T15:32:03.837Z",
      "location_count": 1,
      "location_summary": "Wilmington, North Carolina",
      "locations": [
        {
          "city": "Wilmington",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05269082"
    },
    {
      "nct_id": "NCT01984424",
      "title": "Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hyperlipidemia"
      ],
      "interventions": [
        {
          "name": "Atorvastatin",
          "type": "DRUG"
        },
        {
          "name": "Placebo to Atorvastatin",
          "type": "DRUG"
        },
        {
          "name": "Placebo to Ezetimibe",
          "type": "OTHER"
        },
        {
          "name": "Ezetimibe",
          "type": "DRUG"
        },
        {
          "name": "Placebo to Evolocumab",
          "type": "OTHER"
        },
        {
          "name": "Evolocumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 511,
      "start_date": "2013-12-10",
      "completion_date": "2017-11-21",
      "has_results": true,
      "last_update_posted_date": "2018-11-29",
      "last_synced_at": "2026-11-02T15:32:03.837Z",
      "location_count": 18,
      "location_summary": "Beverly Hills, California • Huntington Beach, California • Los Angeles, California + 15 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Pedro",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01984424"
    },
    {
      "nct_id": "NCT04734210",
      "title": "Research Study To See How Well An Eye Drop (SURF-200) Works, What Side Effects There Are, And To Compare It With Vehicle In Subjects With An Episodic Flare-Up of Dry Eye Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye Disease"
      ],
      "interventions": [
        {
          "name": "0.02% Betamethasone Sodium Phosphate",
          "type": "DRUG"
        },
        {
          "name": "0.04% Betamethasone Sodium Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Surface Ophthalmics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 139,
      "start_date": "2021-01-07",
      "completion_date": "2022-10-12",
      "has_results": true,
      "last_update_posted_date": "2025-06-04",
      "last_synced_at": "2026-11-02T15:32:03.837Z",
      "location_count": 28,
      "location_summary": "Dothan, Alabama • Azusa, California • Mission Hills, California + 25 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Azusa",
          "state": "California"
        },
        {
          "city": "Mission Hills",
          "state": "California"
        },
        {
          "city": "Murrieta",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04734210"
    },
    {
      "nct_id": "NCT01852383",
      "title": "Duloxetine Treatment in Elderly With Dysthymia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Depression",
        "Dysthymic Disorder"
      ],
      "interventions": [
        {
          "name": "Duloxetine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New York State Psychiatric Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "95 Years",
        "sex": "ALL",
        "summary": "60 Years to 95 Years"
      },
      "enrollment_count": 30,
      "start_date": "2006-01",
      "completion_date": "2013-03",
      "has_results": true,
      "last_update_posted_date": "2014-05-01",
      "last_synced_at": "2026-11-02T15:32:03.837Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01852383"
    },
    {
      "nct_id": "NCT04857359",
      "title": "Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Parkinson Disease",
        "Dyskinesia, Drug-Induced",
        "Dyskinesias"
      ],
      "interventions": [
        {
          "name": "Dipraglurant",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Addex Pharma S.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "30 Years to 85 Years"
      },
      "enrollment_count": 25,
      "start_date": "2021-08-06",
      "completion_date": "2022-08-15",
      "has_results": false,
      "last_update_posted_date": "2025-08-06",
      "last_synced_at": "2026-11-02T15:32:03.837Z",
      "location_count": 41,
      "location_summary": "Phoenix, Arizona • Fresno, California • Irvine, California + 38 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04857359"
    }
  ]
}